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Expression Quantitative Trait Locus Analysis in Systemic 
Sclerosis Identifies New Candidate Genes Associated With 
Multiple Aspects of Disease Pathology
Martin Kerick,1  David González- Serna,1  Elena Carnero- Montoro,2 Maria Teruel,2 Marialbert Acosta- Herrera,1 
Zuzanna Makowska,3 Anne Buttgereit,3 Sepideh Babaei,3 Guillermo Barturen,2  Elena López- Isac,1 
PRECISESADS Clinical Consortium, Ralf Lesche,3 Lorenzo Beretta,4  Marta E. Alarcon- Riquelme,2  and 
Javier Martin1
Objective. To identify the genetic variants that affect gene expression (expression quantitative trait loci [eQTLs]) 
in systemic sclerosis (SSc) and to investigate their role in the pathogenesis of the disease.
Methods. We performed an eQTL analysis using whole- blood sequencing data from 333 SSc patients and 524 
controls and integrated them with SSc genome- wide association study (GWAS) data. We integrated our findings 
from expression modeling, differential expression analysis, and transcription factor binding site enrichment with key 
clinical features of SSc.
Results. We detected 49,123 validated cis- eQTLs from 4,539 SSc- associated single- nucleotide polymorphisms 
(SNPs) (PGWAS < 10
−5). A total of 1,436 genes were within 1 Mb of the 4,539 SSc-associated SNPs. Of those 1,436 genes, 
565 were detected as having ≥1 eQTL with an SSc-associated SNP. We developed a strategy to prioritize disease- 
associated genes based on their expression variance explained by SSc eQTLs (r2 > 0.05). As a result, 233 candidates 
were identified, 134 (58%) of them associated with hallmarks of SSc and 105 (45%) of them differentially expressed in the 
blood cells, skin, or lung tissue of SSc patients. Transcription factor binding site analysis revealed enriched motifs of 24 
transcription factors (5%) among SSc eQTLs, 5 of which were found to be differentially regulated in the blood cells (ELF1 
and MGA), skin (KLF4 and ID4), and lungs (TBX4) of SSc patients. Ten candidate genes (4%) can be targeted by approved 
medications for immune- mediated diseases, of which only 3 have been tested in clinical trials in patients with SSc.
Conclusion. The findings of the present study indicate a new layer to the molecular complexity of SSc, contributing 
to a better understanding of the pathogenesis of the disease.
INTRODUCTION
Systemic sclerosis (SSc) is a chronic rheumatic autoimmune 
disease with a high degree of clinical heterogeneity that affects the 
connective tissue (1), and with one of the highest mortality rates 
among rheumatic diseases (2). The pathogenesis of SSc is often 
characterized by a triad of hallmarks: immune dysfunction, fibro-
sis, and vasculopathy. Immune dysfunction involves autoimmune 
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processes and inflammation as a result of an imbalance in T cell, 
B cell, and macrophage activation (1). Fibrosis occurs as a result 
of the activation of fibroblasts, epithelial– mesenchymal transition, 
and excessive extracellular matrix deposition (3). Vasculopathy 
typically consists of a loss of small vessels followed by impaired 
compensatory vasculogenesis and angiogenesis (4). The relation-
ship between immune dysfunction, vascular damage, and fibrosis 
remains fairly unknown.
Like most autoimmune diseases, SSc has a complex etiol-
ogy and a poorly understood genetic component. In this regard, 
substantial efforts have been made to identify genetic features that 
contribute to disease susceptibility. To date, large- scale genetic 
studies have identified up to 27 loci associated with SSc at the 
genome- wide level of significance (P < 5.0 × 10−8) (5– 7), including 
the HLA region (8). Those studies provide invaluable information 
on disease etiopathogenesis, contributing to drug discovery and 
repurposing (9,10). Nevertheless, most of the single- nucleotide 
polymorphisms (SNPs) associated with SSc map to noncoding 
regions of the genome.
A number of SSc- associated loci could be involved in the 
regulation of gene expression, acting as expression quantita-
tive trait loci (eQTLs), which have a widespread presence in the 
genome (11). Analysis of eQTLs can provide a mechanical link 
between a variant and its effect on gene expression, and mul-
tiple eQTLs can be used to explain or model gene expression 
variance. In this regard, eQTL analyses have been successfully 
conducted in other autoimmune diseases such as systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (RA), among oth-
ers (12,13). Interestingly, variants mapped to noncoding enhancer 
regions across 6 autoimmune diseases led to the development of 
a multiple- enhancer variant hypothesis. According to this theory, 
the contribution of several SNPs in linkage disequilibrium at the 
same loci can influence multiple enhancers and be assigned to 
common pathways (12). Furthermore, eQTLs have been identi-
fied in specific cell subsets (14) and have been applied to autoim-
mune disease prognostics (15), which illustrates the relevance of 
these analyses in understanding the pathogenesis of the autoim-
mune process. In this study, we aimed to explore the cis- genetic 
effects of SSc- associated risk loci on expression and performed 
an eQTL analysis using whole- blood RNA sequencing data from 
857 samples.
PATIENTS AND METHODS
Patients and controls. For additional details regarding 
all methods, see the Supplementary Methods, available on the 
Arthritis & Rheumatology website at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41657/ abstract. This study included 333 
patients of European descent who were diagnosed as hav-
ing SSc according to the American College of Rheumatology 
(ACR)/European Alliance of Associations for Rheumatology 
(EULAR) 2013 criteria (16) and were participants in the PRECISE 
Systemic Autoimmune Diseases (PRECISEADS) project (https://
clini caltr ials.gov/ct2/show/NCT02 890134). See Appendix A for 
members of the PRECISESADS Clinical Consortium. A total of 
524 age- and sex- matched controls without known autoimmune 
disease were selected. Patients and controls were randomly 
grouped into equal size discovery and validation sets, matched 
for age, sex, and medication use. Supplementary Table 1, availa-
ble on the Arthritis & Rheumatology website at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41657/ abstract, describes the charac-
teristics of the 2 patient sets. All patients and controls gave written 
informed consent, which was approved by local ethics committees. 
For additional details on ethics approvals, see the Supplementary 
Methods, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41657/ abstract.
RNA sequencing and genotyping. RNA sequencing data 
were obtained and processed as described by Beretta et al (17). 
Genetic data were obtained using the Illumina SNP chip genome- 
wide association study (GWAS) platforms HumanCore- 12- v1, 
Infinium CoreExome- 24v1- 2, and Infinium CoreExome- 24v1- 3. 
Only SNPs typed on all 3 platforms were used for imputation and 
analysis. Samples were subjected to strict quality filtering ana-
lyzed for ancestry and identity. Imputation was performed on the 
Michigan Imputation Server and filtered for quality, minor allele fre-
quency (MAF) > 0.05, and Hardy- Weinberg equilibrium. Raw data 
are the property of the PRECISESADS Consortium. Metadata and 
aggregated data are available upon request from the correspond-
ing author.
Detection of eQTLs. RNA- Seq and genetic data were 
checked to exclude mismatched samples using sex prediction 
and genotype mismatches using an in- house pipeline. Our anal-
ysis was limited to 4,539 candidate SNPs that showed at least a 
suggestive level of association with SSc (PGWAS < 1 × 10
−5 in the 
study by López- Isac et al [5]). SNPs with high linkage disequilib-
rium (≥0.8) were added to the candidate SNPs, totaling 13,253 
SNPs. We used the Matrix eQTL R package (18) and fit a lin-
ear regression model that tests the influence of the number of 
risk alleles on gene expression residuals obtained by correcting 
for potential confounders (i.e., population substructure) using the 
strategy described by Westra et al (12) based on principal com-
ponents. For SNPs with a MAF of <0.1, we additionally calculated 
a dominant model to keep in check excessive influence of low 
numbers of homozygotes of the minor allele. The eQTLs of SNPs 
with a MAF of <0.1 were discarded if they were not significant at 
a false discovery rate (FDR) of <0.05 in both the linear and dom-
inant models.
Our analyses were focused on cis- eQTLs in a window of 1 mil-
lion bp around the transcription start site of a gene, which implies 
1,436 genes, given the 13,253 candidate SNPs. The eQTLs were 
identified for the SSc and control groups separately to avoid inter-
action effects, and we split the groups equally into discovery and 
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replication sets. An FDR of <0.05 defined significant genetic effects 
on gene expression. The eQTLs were considered validated if they 
were found in 2 sets, using a stringent cutoff (FDR <0.05) in one set 
and a nominal P value cutoff (P < 0.05) in the other. To expand on 
sensitivity and to aid finding SSc- specific eQTLs we created a “val-
idated across groups” set of eQTLs, using the strategy described 
above, but this time validating eQTLs obtained from all SSc sam-
ples with eQTLs obtained from all control samples and vice versa. 
In the first run, eQTLs and genes whose expression was associ-
ated with ≥1 eQTL (eGenes) were detected for SNPs associated 
with SSc. In the second run, we detected eQTLs for all SNPs within 
a distance of 1 Mb of an eGene detected in the first run, including 
SNPs unrelated to SSc.
SSc eQTLs were identified as “SSc- specific” if the eQTL was 
validated using the 2 SSc subsets and was not found in any of 
the control data sets or the validated- across- groups data set at 
a nominal cutoff level of 0.1. Candidate SSc- specific eQTLs were 
compared to public databases of blood eQTLs from healthy sub-
jects (Genotype- Tissue Expression [GTEx] Project V7) (11,12); 
27% of these eQTLs had proxy SNPs, which were found with their 
respective gene in one of these databases and were no longer 
considered SSc- specific. We repeated eQTL detection for the 
subset of SSc patients who had received no known medication, 
following the discovery and replication strategy described above 
to find additional SSc- specific eQTLs.
Stepwise linear regression (forward selection). Inde-
pendent eQTL signals that influence the expression of a gene 
were determined following a stepwise linear regression procedure. 
Forward selection was repeated until no additional signal was 
detected at a nominal P level of P < 0.05. This was done for SNP– 
eGene combinations obtained from the analysis described above.
Differential expression analysis. The edgeR package 
in R was used to calculate differential expression in the 7 most 
abundant cell types using cellular composition of whole blood as 
a covariate, as estimated from expression profiles using CIBER-
SORT (19). Additional covariates were disease, sex, age, medica-
tion, and age– cell, medication– cell, disease– sex, and disease– age 
interactions. For additional details, see the Supplementary Meth-
ods, available on the Arthritis & Rheumatology website at http://
onlin elibr ary.wiley.com/doi/10.1002/art.41657/ abstract. Differen-
tial expression data for skin and lung tissues were obtained either 
from published tables (20,21) or by using the default analysis in 
GEO (GEO2R) with the GSE58095 data set comparing all cases 
against all controls.
Transcription factor binding site analysis. Only the 
SSc- associated SNPs (PGWAS < 10
−5) that were part of the best 
expression models obtained by stepwise linear regression analy-
sis (forward selection) were analyzed. Using the R package TFB-
STools (22), we obtained all potential transcription factor binding 
sites and scored the effect of each SNP on transcription factor 
binding. If enrichment was significant (FDR <0.1) for ≥3 scores, 
the overall enrichment of the particular transcription factor bind-
ing site was considered significant. To calculate enrichment, Fish-
er’s exact test was performed with a random selection of 50,000 
eQTLs from the GTEx database V7 (matched for MAF and dis-
tance to transcription start site) as background.
Drug target analysis. We retrieved 2,384 different drugs 
and their 1,138 target genes from the Open Targets database in 
October 2019. Medications used for rheumatic and skin- related 
diseases were extracted from the same database, yielding 542 
drugs currently used to treat these diseases.
Tissue enrichment analysis. A baseline enrichment of 
blood eQTLs was calculated in all tissues using the GTEx data-
base V7. Using a z- test, we investigated whether the enrichment 
of blood eQTLs obtained in this study was even higher than the 
baseline enrichment of all tissues.
RESULTS
Study design, gene and eQTL numbers, and com ­
parison to external data sets. We aimed to explore the cis- 
genetic effects of SSc- associated risk loci on expression in SSc 
and control data sets to detect potential disease- specific eQTLs 
and to model gene expression variation for gene prioritization. Pri-
oritized genes were analyzed for SSc hallmarks and drug repur-
posing, and selected eQTLs were analyzed for transcription factor 
binding site and tissue enrichment. Supplementary Figure 1, avail-
able on the Arthritis & Rheumatology website at http://onlin e 
library.wiley.com/doi/10.1002/art.41657/ abstract, gives an over-
view of all analyses performed.
A total of 18,507 and 38,600 replicated cis- eQTLs were 
identified in SSc patients and controls, respectively, affect-
ing the expression of 137 and 200 genes (eGenes), respec-
tively. After validating across groups of eQTLs found in all SSc 
patients with eQTLs found in controls, and vice versa, a total 
of 49,123 eQTLs were identified, influencing 236 eGenes with 
a median of 73 eQTLs per gene. The maximum number of 
eGenes detected in any of the data sets at a nominal level 
(P < 0.01) was 565, among them 64 long noncoding RNAs 
like XXbac- BPG181B23.7 (lnc- HLA– B- 2:3), TAPSAR1, or 
HCG11 (see Supplementary Table 2, available on the Arthri-
tis & Rheumatology website at http:// onlin e libr ary.wiley.com/
doi/10.1002/art.41657/ abstract).
The eQTLs (a) of the 2 discovery sets, (b) validated across 
groups, and (c) at the intersection of validated control and vali-
dated SSc eQTLs were compared against the GTEx database, 
and 66%, 15%, and 8% unknown eQTLs, respectively, were 
found, which depicts the different levels of stringency of our setup. 
Of interest, 95% of the eQTLs in our whole- blood data set that 
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overlapped with the GTEx database were found in multiple tissues 
according to GTEx.
SSc- specific eQTLs. The eQTLs replicated in SSc whole 
blood were compared to eQTLs observed in control data sets 
with low stringency (nominal P < 0.1). We found 59 eQTLs from 
16 genes potentially specific to SSc. Repeating our analysis in 
a subset of patients who did not receive immunomodulating 
drugs revealed 28 additional eQTLs and 6 additional genes. In- 
depth comparison to known blood eQTLs from heathy controls 
(GTEx V7) (11,12) and their proxies (r2 > 0.8) excluded 24 eQTLs 
(27%) from being SSc- specific. Careful examination suggested 
eQTLs from HLA– B, NCR3, RAF1, NEU1, HLA– DQA1, HLA– 
DOB, HID1, and IER3 to be the best candidates for SSc- specific 
eQTLs (Figure 1 and Supplementary Figure 2, available on the 
Arthritis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41657/ abstract).
Enrichment of blood eQTLs in tissues affected by dis­
ease. We explored whether the validated blood eQTLs from SSc 
patients could be interpreted in other contexts beyond immunity. 
The GTEx database provides a comprehensive overview of eQTL 
Figure 1. Expression quantitative trait loci found in patients with systemic sclerosis (SSc) (blue) but not in controls (gray). Residual expression 
levels, determined using principal components analysis, of the genes HLA– B (A), NCR3 (B), IER3 (C), and RAF1 (D) are shown for the indicated 
genotypes in controls and SSc patients. The number of minor alleles, the risk genotype, and single- nucleotide polymorphisms are indicated on 
the x- axis. Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines 
outside the boxes represent the 10th and 90th percentiles. Circles represent individual subjects.
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sharing among 49 different tissues. Using a meta- analysis pub-
lished by GTEx V7, we found that only 6% of eQTLs are tissue- 
specific, 81% have been detected in ≥5 tissues, and 15% are 
present in >90% of tissues. This clearly shows that eQTLs detected 
in blood can be interpreted functionally in other tissues. Indeed, 
95% of the GTEx- known eQTLs detected in this study are found 
in ≥10 different tissues apart from blood. We investigated whether 
the eQTLs identified in our study were enriched in the GTEx eQTLs 
of non- blood tissues to test our assumptions on interpretability 
beyond the context of whole blood. A significant enrichment was 
found in 19 tissues (Figure 2), the majority of which can readily 
be interpreted in the context of SSc, as the disease affects many 
tissues, such as the lungs, heart, and esophagus.
Expression variance explained (EVE) can be used to 
prioritize SSc eQTLs and SSc eGenes. While many eGenes with 
an SSc- specific eQTL can probably explain the pathogenesis of SSc 
at least partially (Supplementary Table 2, available on the Arthritis & 
Rheumatology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41657/ abstract), we decided to focus on the candidate eGenes 
that are most affected by SSc genetics.
To measure the influence of genetics on gene expression, 
we used a stepwise modeling procedure to obtain independent 
eQTLs per gene and calculate the EVE. Comparing the EVE using 
only SSc- specific eQTLs (EVESSc) against the EVE using all eQTLs 
(EVEall; including eQTLs unrelated to SSc) we obtained a meas-
ure (ratio) of how much EVE can be attributed to SSc genetics. 
Figure 3A depicts a comparison of the 2 calculated EVE values. 
For 104 eGenes (18%), the EVE differed by <30%. One hundred 
thirty eGenes (23%) showed stronger differences in EVE, but still 
had an EVESSc of >0.05 (r
2 > 0.05). The remaining 331 eGenes 
had a low EVESSc (< 0.05), and the EVE differed by >30%. This 
comparison distinguished 3 groups with high, intermediate, and 
low influence of SSc genetics.
Three groups of eGenes were identified based on the impact 
that SSc genetics had on their expression. We analyzed these 
Figure 2. Enrichment of blood expression quantitative trait loci in disease- relevant tissues in patients with systemic sclerosis. Asterisks inside 
the bars indicate the level of significance adjusted for multiple testing (false discovery rate), corresponding to the values shown on the right. 
GTEx = Genotype- Tissue Expression.
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groups for enriched pathways (FDR < 0.05) (Supplementary Tables 
3 and 4, available on the Arthritis & Rheumatology website at http://
onlin elibr ary.wiley.com/doi/10.1002/art.41657/ abstract), and bio-
logic processes from gene ontology, and found that 52% of eGenes 
in the high- or intermediate- impact group (122 of 233) were located 
in immune- related pathways, as compared to only 17% of eGenes 
in the low- impact group (Supplementary Table 2). An in- depth review 
of the literature and gene ontologies helped us assign 66 and 31 
eGenes to SSc- related biologic processes linked to fibrosis and vas-
culopathy, respectively. Many of these eGenes belong to the high- or 
intermediate- impact group (Figures 3B– D). The eGenes for which 
SSc genetics have an intermediate or high impact on expression 
are most likely to shed light on the complex pathology of this disease.
SSc eGenes grouped by the hallmarks of SSc 
 pathogenesis. Three features of SSc pathogenesis can be 
attributed to 134 of the 233 eGenes (58%) for which SSc genetics 
had an intermediate- to- high impact on expression, namely: alter-
ation of immune response, fibrosis, and vasculopathy (Table 1 and 
Supplementary Table 2). The genes implicated in innate and adap-
tive immune cell processes represent the largest subgroup, with 
122 eGenes. Interestingly, 27 HLA eGenes and 8 eGenes related 
to interferon (IFN) pathways were identified, including important 
SSc- associated susceptibility loci dysregulated in SSc (9,23,24). 
Furthermore, there were 27 SSc eGenes associated with biologic 
processes related to fibrosis, and 16 eGenes related to vascu-
lopathy or angiogenesis. These pathways are considered to be 
Figure 3. Gene expression variance explained by expression quantitative trait loci (eQTLs) can distinguish levels of influence of systemic sclerosis 
(SSc) genetics on expression and prioritize genes affected by eQTLs. The expression variance explained (r2) by eQTLs associated with SSc in a recent 
genome- wide association study (using single- nucleotide polymorphisms [SNPs] with association P < 10−5) (5) was plotted against the expression 
variance explained by all eQTLs found within 1 Mb of a gene, whether or not they were associated with SSc. A, Groups of eGenes showing strong (red), 
intermediate (yellow), or weak (blue) influence of SSc genetics. B– D, Same eGenes as shown in A. Highlighted are eGenes related to B, fibrosis (yellow), 
C, vascular processes (red), and D, immunity (blue). The eGenes not related to any of these hallmarks are depicted in black.
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Table 1. Differentially expressed eGenes associated with hallmarks of SSc*
Gene




Differential expression  
(log2 fold change)†
Immunity Fibrosis Vascular Blood Skin Lungs
AGER High + − + −5.31 – – 
BLK High + − − – 0.1 – 
C2 High + − − – 0.45 – 
C4A High + − − −19.33 – – 
C4B High + − − −19.57 – – 
CCHCR1 High + − − −4.58 – – 
CFB High + − − – 0.4 – 
DDAH2 High + − + −4.28 – – 
HLA– B High + − − −4.49 – – 
HLA– DPA1 High + − − – 0.34 1.07
HLA– DQA1 High + − − – – 1.04
HLA– DQB1 High + + − – 0.48 – 
HLA– DRA High + − − – 0.29 1.09
HLA– DRB5 High + − − – – 1.25
HLA– DRB6 High + − − – 0.29 – 
HSPA1B High + − − −7.14 – – 
LST1 High + − − −5.72 0.23 – 
LTB High + + − −7.68 0.64 – 
LY6G5C High + − − −9.78 0.11 – 
MICA High + − − −6.29 – – 
MICB High + − − – 0.21 – 
NCR3 High + − − −9.71 – – 
NEU1 High + − − – 0.15 – 
NOTCH4 High + + + – 0.23 – 
RAB2A High + − − – −0.21 – 
RNF5 High + − − −4.84 – – 
TAP1 High + − − – – 1.23
TNXB High + + − −7.01 – – 
AIF1 Intermediate + − − −5.32 – – 
CCDC104 Intermediate + − − −3.71 – – 
CD151 Intermediate + − − −6.94 0.3 – 
CD247 Intermediate + − − −4.27 – – 
CD40 Intermediate + + + – 0.19 – 
CTSB Intermediate + + − – 0.4 1.14
ELMO1 Intermediate + − − 5.56 – – 
ERAP1 Intermediate + − + 5.11 – – 
FLNB Intermediate + + − 3.43 0.13 – 
GTF2H4 Intermediate + − − – 0.19 – 
HLA– A Intermediate + − − – 0.25 1.06
HLA– DMA Intermediate + − − – 0.36 1.05
HLA– DMB Intermediate + − − – 0.32 1.05
HLA– DOA Intermediate + − − 5.42 0.2 – 
HLA– F Intermediate + − − −4.63 – – 
HLA– H Intermediate + − − – 0.23 0.99
HSPA1L Intermediate + − − −4.42 −0.14 – 
IDUA Intermediate + + − – 0.26 – 
IER3 Intermediate + − + – – 1.15
IFI30 Intermediate + + − −3.78 – – 
MPI Intermediate + − − −2.73 – – 
MSRA Intermediate + − − – 0.15 – 
PSMB8 Intermediate + + + −4.49 – – 
PSMB9 Intermediate + − − – 0.29 – 
PXK Intermediate + − − 2.91 – – 
RXRB Intermediate + − − – 0.15 – 
SUMO2 Intermediate + − − – −0.21 – 
TAPBP Intermediate + − − – 0.24 – 
TNPO3 Intermediate + − − 5.64 – – 
TUBB Intermediate + − − – 0.16 – 
UBE2L3 Intermediate + − − −2.25 – – 
 (Continued)
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potential targets of future disease- modifying therapies for SSc 
(25). Of interest, we also found 25 eGenes related to apoptotic 
processes, which support the hypothesis of a relevant role of 
apoptosis in SSc (26).
Differential expression of SSc eGenes in disease- 
affected tissues. Given that the SSc- specific eQTLs detected 
in whole blood were observed to be enriched in other tissues 
affected by the disease, we decided to analyze the expression 
of the prioritized 233 SSc eGenes in the skin, lungs, and 7 blood 
cell types using public data sets (20,21) (GSE58095) and our 
whole- blood data set, with deconvolution of blood cell compo-
sitions. The data are presented in Table 1 and Supplementary 
Table 2.
One hundred five SSc eGenes (45%) were found to be dif-
ferentially regulated in one of the tissues investigated. A total of 
57 SSc eGenes (24%) were down- regulated in 1 of the 3 tissues 
investigated, whereas 55 SSc eGenes (24%) were up- regulated. 
In addition, 40 SSc eGenes (17%) were differentially expressed in 
the skin of SSc patients. A total of 11 eGenes (5%) were found to 
be differentially regulated in the lung samples and lung fibroblast 
cultures from SSc patients. Differential expression analysis of 7 
blood cell types in SSc revealed 72 SSc eGenes (31%), most of 
which (99%) showed a consistent direction of regulation (up or 
down) in ≥5 cell types.
Results of transcription factor binding site analysis. 
We investigated transcription factor binding site enrichment in 
SSc eQTLs. Only the independent eQTLs included in the models 
that best predicted eGene expression, as determined by stepwise 
linear regression, were included. Then, transcription factor bind-
ing site enrichment was estimated, as compared to genome- wide 
eQTLs from the GTEx database, to control for the fact that all 
transcription factor binding site motifs are highly enriched in eQTL 
sites in general.
Of the 537 transcription factor binding site profiles assessed 
(JASPAR database 2018), 24 (5%) were stably enriched (see 
Patients and Methods) in best- model SSc eQTLs (Supplementary 
Table 5, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41657/ abstract). 
The transcription factors were of different classes, with 5 home-
odomain transcription factors, 4 transcription factors of the T- box 
type, 4 C2H2 transcription factors, and 2 GATA transcription fac-
tors, to name only those with multiple members of the same class. 
Of the 24 transcription factors, we found 10 and 16 transcription 
factors expressed in whole blood and skin, respectively, of which 5 
transcription factors were differentially regulated (FDR < 0.1) in the 
skin, lungs, or blood cells from SSc patients (Table 2). KLF4 and 
ID4 were down- regulated in the skin, TBX4 was up- regulated in 
the lungs, and ELF and MGA were up- regulated in almost all of the 
7 blood cell types assessed (Figure 4 and Supplementary Table 5 
and Supplementary Figure 3, available on the Arthritis & Rheu-
matology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41657/ abstract).
Drug repurposing. We explored whether any of the 233 
eGenes prioritized in the present study encode target proteins 
of drugs being tested in ongoing clinical trials, as reported on 
the Open Targets platform (27). We observed that 15 of the 233 
eGenes (6.4%) overlapped with pharmacologic targets of which 
TNF, BLK, and TUBB have been tested in clinical trials in SSc 
patients.
Gene




Differential expression  
(log2 fold change)†
Immunity Fibrosis Vascular Blood Skin Lungs
UNC119B Intermediate + + − 2.33 – – 
CLIC1 Intermediate − + − −2.9 – – 
FLOT1 Intermediate − + − −4.9 0.28 – 
PHF1 Intermediate − + − −3.38 – – 
RPS18 Intermediate − + − −9.34 – – 
SYNGAP1 Intermediate − + − 3.5 – – 
UQCC2 Intermediate − + − −5.03 – – 
* eGenes = genes whose expression was associated with ≥1 expression quantitative trait loci; SSc = systemic 
sclerosis. 
† Adjusted P < 0.1 for all values shown. 
Table 1. (Cont’d)
Table 2. Differentially expressed transcription factors with enriched 
binding sites in SSc- associated eQTLs in expression models*
Differential expression  
(log2 fold change)†
Gene Transcription factor class Blood Skin Lung
ELF1 Ets 4.68 – – 
MGA T- box 4.3 – – 
KLF4 C2H2 ZF – −0.36 – 
ID4 basic helix- loop- helix NE −0.23 – 
TBX4 T- box NE – 0.74
* SSc = systemic sclerosis; eQTLs = expression quantitative trait loci; 
NE = not expressed (source: European Bioinformatics Institute Gene 
Expression Atlas). 
† Adjusted P < 0.1 for all values shown. 
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Next, we tested whether medications used for other immune- 
mediated diseases (105 antibody- targeted, 48 kinase inhibitor– 
targeted, and 195 receptor- targeted drugs; see Patients and 
Methods) addressed the proteins coded by the SSc eGenes, and 
we found 5 additional SSc eGenes: LTA, LTB, IL12A, CD40, and 
RXRB. Further investigation identified ERAP1 and ERAP2, which 
can be addressed by aminopeptidase inhibitors.
Expression analysis in whole blood, skin, and lung tissues 
revealed that 6 of the 10 drug- target SSc- specific eGenes are dif-
ferentially regulated in the blood cells and/or skin of SSc patients 
(Supplementary Table 6 and Supplementary Figure 4, available 
on the Arthritis & Rheumatology website at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41657/ abstract). In the blood cells 
of SSc patients, ERAP1 was up- regulated, whereas LTB was 
down- regulated. LTB, CD40, RXRB, BLK, and TUBB were up- 
regulated in the skin of SSc patients. In summary, 7 genes that 
have been considered for the treatment of conditions similar to 
SSc are potential candidates for study in clinical trials for SSc.
DISCUSSION
In this study, the integrated analysis of expression and genetic 
data in a large SSc cohort identified novel eQTLs in the whole 
blood of SSc patients, which are enriched in disease- relevant 
tissues. We found 64 eQTLs potentially specific to SSc, which 
were not found in either our cohort of healthy controls or any of 
the public blood eQTL databases (GTEx V7) (11,12). This find-
ing suggests that additional mechanisms exist that render these 
Figure 4. Differential expression of the transcription factors ELF1, MGA, KLF4, and ID4 in patients with systemic sclerosis (SSc) compared 
to controls. A and B, Residual expression of ELF1 in neutrophils (A) and MGA in monocytes (B) from controls and SSc patients. Values on the 
x- axis are the percentage of cells investigated per patient as obtained from the Cell- type Identification by Estimating Relative Subsets of Known 
RNA Transcripts (CIBERSORT) algorithm. ELF1 and MGA were up- regulated in SSc patient tissues. C and D, Log2 expression of KLF4 (C) and 
ID4 (D) in skin from controls and SSc patients. KLF4 and ID4 were down- regulated in SSc patient tissues. Data are shown as box plots. Each 
box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th 
percentiles. Circles represent individual subjects.
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eQTLs active in disease and neutral in healthy subjects. The most 
likely explanation is the differential expression of transcription fac-
tors associated with a disease, as has been suggested previously 
(28,29). Indeed, we showed that of 24 transcription factors asso-
ciated with SSc by our analysis of transcription factor binding site 
enrichment, ≥5 were differentially expressed in disease- relevant 
tissues. The eQTL analysis of the most likely associated SSc risk 
loci, prioritizing genes (eGenes) where SSc eQTLs explain >5% 
of expression variance, led to a strong enrichment of immunity- 
related genes, vasculopathy, and fibrosis. Finally, the findings 
were integrated with current knowledge of SSc pathology, thereby 
identifying useful candidates for drug repurposing.
One of the main findings of the present study is that we could 
assign more than half of the eGenes (n = 134) to hallmarks of 
SSc pathogenesis. Interesting candidates were related to immune 
system processes, fibrosis, and vascular pathologies. Immune 
system processes highlighted eGenes like CD247 or BLK, both 
of them previously associated with SSc and several autoimmune 
diseases such as RA or SLE (7,30,31). Regarding IFN- associated 
eGenes, we identified IRF5 and the 2 IL12 receptors, IL12RA and 
IL12RB, which are well- established SSc risk loci, and are also 
associated with other autoimmune diseases such as RA, SLE, 
and myositis (6,32,33). With regard to fibrosis, TNXB is implicated 
in the regulation of the production and assembly of certain types 
of collagen (34). TNXB is also the main causative gene in Ehlers- 
Danlos syndrome, which is characterized by altered skin elastic-
ity, among other symptoms (35). The eGenes associated with 
vasculopathy or angiogenesis included NOTCH4, a non- classic 
HLA gene in the class II region that regulates NOTCH1 and has 
previously been associated with SSc (36,37), and CD151, which 
is linked to vascular stability and neo- angiogenesis (38). Finally, 
regarding inflammatory processes, C4A and C4B are part of the 
complement system affected by active disease in a number of 
autoimmune diseases (39). Interestingly, a recent study demon-
strated the relevance of the copy number and resulting expression 
levels of C4A and C4B, as well as their contribution to sex- biased 
vulnerability in autoimmunity (40). In this regard, the eQTLs 
described in our study could be acting either as a proxy to C4A- 
C4B copy numbers or as an additional mechanism regulating the 
complex variation of complement genes.
Interestingly, we found 25 eGenes related to apoptosis pro-
cesses. Previous genetic studies have indicated that apoptosis is 
an important mechanism of the disease, revealing the association 
of some genes, such as DNASE1L3 or TNFAIP3, with a higher 
risk of SSc (6,41). We confirm here DNASE1L3, which plays an 
important role in DNA fragmentation during apoptosis (42), as an 
interesting candidate. Another eGene observed with a particu-
lar role in apoptosis was BAK1, which encodes for Bcl- 2 antag-
onist or killer (BAK), one of the principal proapoptotic proteins 
of the mitochondrial pathway (43). Interestingly, a recent study 
showed that dermal fibroblasts derived from patients with SSc 
become particularly susceptible to apoptosis induced by mimetic 
drugs of proapoptotic protein Bcl- 2 homology 3, a direct activator 
of BAK, reducing the fibrotic process (44). Thus, even though the 
specific pathogenic process of apoptosis in SSc is still unknown, 
our results support its role in SSc, which could be key to revers-
ing fibrosis as part of the tissue regeneration process.
It is noteworthy that 50% of the SSc eGenes associated with 
SSc hallmarks overlap with >1 group (Supplementary Table 2). 
This is not surprising, given that, for example, fibrosis, angiogen-
esis, and inflammation are closely linked, which demonstrates the 
complexity of the pathogenesis of SSc. Alternatively, there was 
significant enrichment of eQTLs in 19 tissues, most of them inter-
pretable in the context of SSc, which affects tissues such as the 
lungs, cardiac tissue, and esophagus (1).
A total of 24 transcription factor binding sites were stably 
enriched in best- model SSc- specific eQTLs. In this regard, the tran-
scription factor ELF1 (E74- like ETS transcription factor 1) deserves 
special mention, as it was also found to be differentially up- regulated 
in almost all 7 blood cell types assessed. ELF1 belongs to the ETS 
family of transcription factors that regulate the expression of a wide 
range of genes and play an important role in immune cell devel-
opment and function and in angiogenesis (45,46). This transcrip-
tion factor activates the expression of several T cell genes. One of 
them is the gene encoding the ζ chain of the T cell receptor (TCR), 
a molecule with a primary function in the transduction of intracellular 
signals that influence positive and negative selection of T cells upon 
TCR ligation (47). On the other hand, ELF1 also plays an important 
role in B cells by cooperating with members of the activator protein 
1 family of transcription factors to activate the 3′ immunoglobulin 
heavy- chain enhancer upon IgM stimulation, which could contrib-
ute to class- switch recombination (48). Of note, our enrichment 
analysis of transcription factor binding sites has to be interpreted 
with caution as the independence assumption of Fisher’s exact 
test might not be fully met, since stepwise modeling does not nec-
essarily generate independent loci for enrichment analysis.
Candidate eGenes identified here overlap with eQTL anal-
yses performed in other autoimmune diseases, further support-
ing our results and manifesting the shared genetic component of 
autoimmune diseases. Some eGenes, such as BLK, GSDMB, 
and ORMDL3 which have been described to be involved in RA 
(49), KRT8P46, GSDMB, and ORMDL3 in multiple sclerosis (MS) 
(50), ANO9 and BLK in SLE (51), and GSMDA, GSDMB, and 
ORMDL3 in type 1 diabetes mellitus (52), were also significantly 
associated in our study.
Given the surprisingly high amount of candidate genes that 
warrant further studies, it is important to address the limits of this 
study. First, this study focused on bulk RNA- Seq and identified 
eQTLs present in the most abundant blood cell types. Although 
tools like CIBERSORT can successfully estimate the abundance 
of various cell types present, the number of samples needed to 
identify cell- specific eQTLs even in the most abundant cell types 
using bulk RNA- Seq are still prohibitive (12). Second, although 
we highlight genes for which interpretation in the context of the 
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disease is best understood in tissues other than blood, single- cell 
studies in SSc- affected tissues are needed to confirm and expand 
our findings. Last, we did not distinguish between the most com-
mon forms of SSc (limited cutaneous and diffuse cutaneous), nor 
did we analyze data on autoantibodies, as data were only avail-
able for a subset of the samples and would have severely dimin-
ished the sensitivity of our analysis.
The validation of the eQTLs identified from peripheral 
blood mononuclear cells (PBMCs) in other tissues as presented in 
the GTEx database opens the way to cautiously use blood eQTLs 
as a proxy to detect eQTLs that most likely exert their main effect 
in tissues other than blood. Interestingly, Beretta et al recently 
observed a strong enrichment of several IFN- related pathways in 
the first whole- blood transcriptome profiling performed in a large 
cohort of SSc patients (17). Furthermore, a recent analysis of 
whole transcriptome expression in the skin of patients with early 
diffuse SSc revealed a high prevalence of both innate and adap-
tive immune cell activity (53). These results are concordant with 
the clear enrichment of immunity- related eGenes observed in our 
study and represent a support of the use of PBMC expression 
data as surrogate markers of organ disease.
To sum up, this is the first eQTL analysis performed in PBMCs 
of SSc patients, revealing that more than half of the eGenes 
detected were associated with the most important SSc hallmarks 
and highlighting the apoptotic process. Furthermore, we identi-
fied enriched motifs for transcription factors in SSc eQTLs that 
are differentially regulated in blood, skin, or the lungs. Our results 
highlight the role of the clinical features and tissues involved in 
SSc, adding a new layer of complexity and contributing to a better 
understanding of SSc pathogenesis.
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APPENDIX A: THE PRECISESADS Clinical Consortium
Members of the PRECISESADS Clinical Consortium are as follows: 
Lorenzo Beretta, Barbara Vigone (Referral Center for Systemic 
 Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale 
 Maggiore Policlinico di Milano, Italy); Jacques- Olivier Pers, Alain Saraux, 
Valérie Devauchelle- Pensec, Divi Cornec, Sandrine Jousse- Joulin (Cen-
tre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, 
France); Bernard Lauwerys, Julie Ducreux, Anne- Lise Maudoux (Pôle de 
pathologies rhumatismales systémiques et inflammatoires, Institut de 
Recherche Expérimentale et Clinique, Université catholique de Louvain, 
Brussels, Belgium); Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, 
Raquel Faria, Mariana Brandão, Ana Campar, António Marinho, Fátima 
Farinha, Isabel Almeida (Centro Hospitalar do Porto, Portugal); Miguel 
Angel Gonzalez- Gay Mantecón, Ricardo Blanco Alonso, Alfonso Corrales 
Martínez (Servicio Cantabro de Salud, Hospital Universitario Marqués de 
Valdecilla, Santander, Spain); Ricard Cervera, Ignasi Rodríguez- Pintó, 
Gerard Espinosa (Hospital Clinic I Provicia, Institut d’Investigacions 
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Biomèdiques August Pi i Sunyer, Barcelona, Spain); Rik Lories, Ellen De 
Langhe (Katholieke Universiteit Leuven, Belgium); Nicolas Hunzelmann, 
Doreen Belz (Klinikum der Universitaet zu Koeln, Cologne, Germany); 
Torsten Witte, Niklas Baerlecken (Medizinische Hochschule Hannover, 
Germany); Georg Stummvoll, Michael Zauner, Michaela Lehner (Medical 
University Vienna, Vienna, Austria); Eduardo Collantes, Rafaela Ortega- 
Castro, Mª Angeles Aguirre- Zamorano, Alejandro Escudero- Contreras, 
Mª Carmen Castro- Villegas (Servicio Andaluz de Salud, Hospital Uni-
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